Analyst Price Targets — MRSH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 10:41 am | Strong Buy | Raymond James | $225.00 | $174.06 | TheFly | Marsh McLennan upgraded to Strong Buy from Outperform at Raymond James |
| February 2, 2026 1:13 pm | — | Cantor Fitzgerald | $212.00 | $190.46 | TheFly | Marsh McLennan price target raised to $212 from $208 at Cantor Fitzgerald |
| February 2, 2026 12:22 pm | — | Mizuho Securities | $213.00 | $188.19 | TheFly | Marsh McLennan price target raised to $213 from $212 at Mizuho |
| January 14, 2026 1:16 pm | — | Cantor Fitzgerald | $208.00 | $182.70 | TheFly | Marsh McLennan price target lowered to $208 from $226 at Cantor Fitzgerald |
| January 13, 2026 11:43 am | Elyse Greenspan | Wells Fargo | $199.00 | $185.63 | TheFly | Marsh McLennan price target lowered to $199 from $212 at Wells Fargo |
| January 8, 2026 12:30 pm | Alex Scott | Barclays | $210.00 | $182.90 | TheFly | Marsh McLennan price target raised to $210 from $206 at Barclays |
| January 7, 2026 9:46 pm | Robert Cox | Goldman Sachs | $199.00 | $182.90 | TheFly | Marsh McLennan price target raised to $199 from $196 at Goldman Sachs |
| January 7, 2026 1:01 pm | — | Evercore ISI | $236.00 | $182.65 | TheFly | Marsh McLennan price target lowered to $236 from $237 at Evercore ISI |
| December 16, 2025 11:16 am | Bob Huang | Morgan Stanley | $190.00 | $187.29 | TheFly | Marsh McLennan price target lowered to $190 from $195 at Morgan Stanley |
| December 15, 2025 9:18 pm | — | Mizuho Securities | $212.00 | $187.29 | TheFly | Marsh McLennan initiated with an Outperform at Mizuho |
Latest News for MRSH
Marsh has increased its dividend for 16 consecutive years. Its 10-year dividend growth rate is 11.3%, which is impressive, but what might be even more impressive is the relentless nature of it. MRSH moved its revenue from $13.2 billion in FY 2016 to $27 billion in FY 2025. That's a compound annual growth rate of 8.3%. Solid. Marsh has a good financial position. The long-term debt/equity ratio is 1.2, while the…
Marsh (NYSE: MRSH - Get Free Report) and Health In Tech (NASDAQ: HIT - Get Free Report) are both financial services companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Valuation and Earnings This table compares Marsh
Marsh is a leading insurance broker, combining organic growth and strategic acquisitions to consolidate a fragmented industry. MRSH posted strong Q4 2025 results: 8.7% revenue growth, 9.8% adjusted EPS growth, and margin expansion to 23.7%. Shares trade at a forward P/E of 16.2, a 19% discount to fair value, with a $210 per share estimate and 16% potential total return through 2026.
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Marsh (NYSE: MRSH) today declared a quarterly dividend of $0.900 per share on outstanding common stock, payable on May 15, 2026, to stockholders of record on April 9, 2026. About Marsh Marsh (NYSE: MRSH) is a global leader in risk, reinsurance and capital, people and investments, and management consulting, advising clients in 130 countries. With annual revenue of…
NEW YORK--(BUSINESS WIRE)--Mercer, a Marsh business (NYSE: MRSH) and a global leader in helping clients realize their investment objectives, shape the future of work and enhance health and retirement outcomes for their people, today released the findings of its Global Talent Trends 2026 report. This landmark survey of nearly 12,000 C-suite executives, HR leaders, investors, and employees worldwide, now in its 11th…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for MRSH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.